Zila results
This article was originally published in The Tan Sheet
Executive Summary
Ester-C and Ester-E revenues rose 33% in the fourth quarter and 24% in fiscal year 2004 (ended July 31), the Phoenix, Ariz.-based firm reports Oct. 14. Zila ramped up production and marketing for the Ester brand by 34% in the fiscal year as the Ester-E line extension rolled out to retailers nationwide in the fourth quarter (1"The Tan Sheet" Aug. 9, 2004, In Brief). Zila's overall sales decreased 7% to $11.1 mil. in part due to discontinued saw palmetto products; the firm's fiscal 2004 sales increased 5% to $49.4 mil...
You may also be interested in...
Bayer Migraine Formula Seeks Market Share Before Excedrin Returns
Bayer Migraine Formula, already in major retailers nationwide, is “a welcome addition to the pain relief aisle for migraine sufferers … affected by the OTC supply issues this year,” the firm says, referring to Novartis’ voluntarily recall of Excedrin.
Bayer Migraine Formula Seeks Market Share Before Excedrin Returns
Bayer Migraine Formula, already in major retailers nationwide, is “a welcome addition to the pain relief aisle for migraine sufferers … affected by the OTC supply issues this year,” the firm says, referring to Novartis’ voluntarily recall of Excedrin.
Sales & Earnings In Brief
GSK core OTCs outpace market growth; Sanofi consumer business surges in emerging markets; broad drivers fuel GNC growth; USANA builds bonds in China; bullish Mead Johnson raises outlook; more Sales & Earnings In Brief.